|Videos|August 13, 2013
Palliative Care and Cancer Pain Management
Advertisement
In this discussion, panelists describe palliative care and pain management for patients with cancer. In order to achieve optimal results, palliative care should play a major role throughout diagnosis, treatment, and into survivorship. In this process, preventative measures should be taken and a healthy lifestyle should be endorsed, in addition to addressing the patient's direct needs. The panelists agree that palliative care should be introduced early in the treatment paradigm, in order to be most effective.
Advertisement
Related to this article
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
Alcohol-attributable cancer deaths in the U.S. doubled from about 11,400 in 1990 to more than 23,100 in 2023.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
2
August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know
3
New Biomarker-Driven Regimens Prompt Debate Over Treatment Intensification in Advanced Prostate Cancer
4
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
5